EyePoint reported mixed results from its LUGANO Phase 3 trial for wet AMD drug DURAVYU, missing the primary endpoint due to a small patient cohort but excelling in key secondary metrics. The company expects data from a second trial in late 2026.
EyePoint reported mixed results from its LUGANO Phase 3 trial for wet AMD drug DURAVYU, missing the primary endpoint due to a small patient cohort but excelling in key secondary metrics. The company expects data from a second trial in late 2026.